BACKGROUND: Resveratrol has been shown to reverse some of the detrimental effects of metabolic syndrome (MetS). We sought to define the impact of supplemental resveratrol on normal myocardium remote from an ischemic territory in a swine model of MetS and chronic myocardial ischemia. STUDY DESIGN: Yorkshire swine were fed a normal diet (control), a high cholesterol diet (HCD), or a high cholesterol diet with orally supplemented resveratrol (HCD-R; 100 mg/kg/day). Four weeks after diet modification, myocardial ischemia was induced by ameroid constrictor placement. Seven weeks later, myocardial tissue from a territory remote from the ischemia was harvested. Animals in the HCD and HCD-R groups underwent functional cardiac MRI before ischemia and before sacrifice. Tissue was harvested for protein expression analysis. RESULTS: After 7 weeks of ischemia, regional left ventricular systolic function was significantly increased in HCD-R as compared with HCD animals. During ventricular pacing the HCD group had significantly decreased flow (p = 0.03); perfusion in the HCD-R was preserved as compared with the control. There was no difference in microvascular relaxation. Expression of metabolic proteins Sirt-1 (p = 0.002), AMPkinase (p = 0.02), and carnitine palmitoyltransferase-I (p = 0.002) were upregulated in the HCD-R group. Levels of protein oxidative stress were significantly increased in the HCD and HCD-R groups, as compared with the controls (p = 0.003). Activated endothelial nitric oxide synthase (eNOS) was increased in the HCD-R group (p = 0.01). There was no difference in myocardial endothelial cell density between the groups; however, dividing endothelial cells were decreased in the HCD and HCD-R groups (p = 0.006). CONCLUSIONS: Resveratrol supplementation improves regional left ventricular function and preserves perfusion to myocardium remote from an area of ischemia in an animal model of metabolic syndrome and chronic myocardial ischemia.
BACKGROUND:Resveratrol has been shown to reverse some of the detrimental effects of metabolic syndrome (MetS). We sought to define the impact of supplemental resveratrol on normal myocardium remote from an ischemic territory in a swine model of MetS and chronic myocardial ischemia. STUDY DESIGN: Yorkshire swine were fed a normal diet (control), a high cholesterol diet (HCD), or a high cholesterol diet with orally supplemented resveratrol (HCD-R; 100 mg/kg/day). Four weeks after diet modification, myocardial ischemia was induced by ameroid constrictor placement. Seven weeks later, myocardial tissue from a territory remote from the ischemia was harvested. Animals in the HCD and HCD-R groups underwent functional cardiac MRI before ischemia and before sacrifice. Tissue was harvested for protein expression analysis. RESULTS: After 7 weeks of ischemia, regional left ventricular systolic function was significantly increased in HCD-R as compared with HCD animals. During ventricular pacing the HCD group had significantly decreased flow (p = 0.03); perfusion in the HCD-R was preserved as compared with the control. There was no difference in microvascular relaxation. Expression of metabolic proteins Sirt-1 (p = 0.002), AMPkinase (p = 0.02), and carnitine palmitoyltransferase-I (p = 0.002) were upregulated in the HCD-R group. Levels of protein oxidative stress were significantly increased in the HCD and HCD-R groups, as compared with the controls (p = 0.003). Activated endothelial nitric oxide synthase (eNOS) was increased in the HCD-R group (p = 0.01). There was no difference in myocardial endothelial cell density between the groups; however, dividing endothelial cells were decreased in the HCD and HCD-R groups (p = 0.006). CONCLUSIONS:Resveratrol supplementation improves regional left ventricular function and preserves perfusion to myocardium remote from an area of ischemia in an animal model of metabolic syndrome and chronic myocardial ischemia.
Authors: Michael P Robich; Robert M Osipov; Louis M Chu; Jun Feng; Thomas A Burgess; Shizu Oyamada; Richard T Clements; Roger J Laham; Frank W Sellke Journal: J Am Coll Surg Date: 2010-08-21 Impact factor: 6.113
Authors: Michael P Robich; Robina Matyal; Louis M Chu; Jun Feng; Shu-Hua Xu; Roger J Laham; Philip E Hess; Cesario Bianchi; Frank W Sellke Journal: J Mol Cell Cardiol Date: 2010-09-06 Impact factor: 5.000
Authors: Joseph T Rodgers; Carlos Lerin; Wilhelm Haas; Steven P Gygi; Bruce M Spiegelman; Pere Puigserver Journal: Nature Date: 2005-03-03 Impact factor: 49.962
Authors: David P Dutka; Michael Pitt; Domenico Pagano; Marco Mongillo; David Gathercole; Robert S Bonser; Paolo G Camici Journal: J Am Coll Cardiol Date: 2006-12-05 Impact factor: 24.094
Authors: Marie-Soleil Beaudoin; Christopher G R Perry; Alicia M Arkell; Adrian Chabowski; Jeremy A Simpson; David C Wright; Graham P Holloway Journal: J Physiol Date: 2014-03-17 Impact factor: 5.182
Authors: Philipp Diehl; Daniel S Gaul; Jonas Sogl; Ulrike Flierl; Darren Henstridge; Juergen Pahla; Heiko Bugger; Maximilian Y Emmert; Frank Ruschitzka; Christoph Bode; Thomas F Lüscher; Martin Moser; Christian M Matter; Karlheinz Peter; Stephan Winnik Journal: J Thromb Thrombolysis Date: 2018-07 Impact factor: 2.300
Authors: Ashraf A Sabe; Nassrene Y Elmadhun; Rahul S Dalal; Michael P Robich; Frank W Sellke Journal: J Thorac Cardiovasc Surg Date: 2013-11-20 Impact factor: 5.209
Authors: Antonio D Lassaletta; Nassrene Y Elmadhun; Yuhong Liu; Jun Feng; Thomas A Burgess; Nicholas W Karlson; Roger J Laham; Frank W Sellke Journal: Circulation Date: 2013-09-10 Impact factor: 29.690
Authors: Martin Wepler; Sebastian Hafner; Angelika Scheuerle; Matthias Reize; Michael Gröger; Florian Wagner; Florian Simon; José Matallo; Frank Gottschalch; Andrea Seifritz; Bettina Stahl; Martin Matejovic; Amar Kapoor; Peter Möller; Enrico Calzia; Michael Georgieff; Ulrich Wachter; Josef A Vogt; Christoph Thiemermann; Peter Radermacher; Oscar McCook Journal: Intensive Care Med Exp Date: 2013-10-29